Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study

(2022) Nicole Wolter et al.   LANCET

Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial

(2022) Lulu Bravo et al.   LANCET

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

(2021) Peter Richmond et al.   LANCET

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

(2021) Jamie Lopez Bernal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis

(2021) Pratha Sah et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hybrid immunity

(2021) Shane Crotty   SCIENCE

Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis

(2021) Yinjun Mao et al.   CHINESE MEDICAL JOURNAL

A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection

(2021) N. Kojima et al.   EVALUATION & THE HEALTH PROFESSIONS

Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2

(2021) Katherine Laiton-Donato et al.   INFECTION GENETICS AND EVOLUTION

Protective Immunity after Natural Infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) – Kentucky, USA, 2020

(2021) Kevin B. Spicer et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar

(2021) Laith J. Abu-Raddad et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

(2021) Sara Y Tartof et al.   LANCET

Waning Immunity after the BNT162b2 Vaccine in Israel

(2021) Yair Goldberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant

(2021) Hiam Chemaitelly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

(2021) Einav G. Levin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Omicron variant and booster COVID-19 vaccines

(2021) Talha Khan Burki   Lancet Respiratory Medicine

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

(2020) Yuan Huang et al.   ACTA PHARMACOLOGICA SINICA